Welcome to our dedicated page for PRF Technologies Ltd. SEC filings (Ticker: PRFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PRF Technologies Ltd. filings document a foreign private issuer with healthcare and solar analytics operations. Current reports on Form 6-K disclose regulatory and development updates for OcuRing™-K, LayerBio’s sustained-release ocular drug-delivery platform, as well as DeepSolar commercial agreements, SaaS deployments, technical due diligence services, patent-related activity, and business updates tied to the company’s operating platforms.
The filing record also covers capital structure and governance matters, including ordinary-share financing arrangements, registration statement incorporation for Form F-3 and Form S-8 purposes, board and executive changes, committee independence, and share-capital actions. PRF’s annual reporting on Form 20-F provides the broader framework for its business, risk factors, operating results, subsidiaries, and public-company controls.
PRF Technologies Ltd. furnished a report highlighting a new step in its energy-technology strategy. The company has filed its first patent application for proprietary methods that model micro-climate conditions at individual solar plants to improve the accuracy of solar energy production forecasts.
The patent application protects core intellectual property behind DeepSolar Predict, PRF’s solar forecasting software platform, and follows the company’s acceptance into the NVIDIA Connect Program. The technology targets a key weakness in conventional solar forecasting, which often relies on broad regional weather data rather than localized conditions that drive actual plant output.
PRF expects that, once commercialized, the DeepSolar Predict platform could help utility-scale solar operators and energy traders optimize dispatch, reduce penalties tied to forecast errors, and enhance financial performance in volatile power markets. This initiative complements PRF’s existing pharmaceutical programs, reflecting a dual focus on extended-release pain therapies and AI-driven renewable energy optimization.
PRF Technologies Ltd., formerly PainReform Ltd., reports that shareholders approved a corporate name change at the January 6, 2026 annual general meeting. The company will continue trading on Nasdaq under the ticker PRFX.
The new name is meant to reflect an evolution from a single-product focus into a diversified innovation platform spanning specialty pharmaceuticals, advanced drug-delivery technologies, and AI-driven renewable-energy analytics. PRF continues to advance its non-opioid postoperative pain therapy PRF-110, while also building its LayerBio ophthalmology platform and DeepSolar AI-driven solar analytics business to pursue growth across healthcare and clean‑energy technology markets.
PainReform Ltd. reported new safety results for OcuRing™-K, a drop-less, sustained-release ocular drug delivery platform being developed with its majority-owned subsidiary LayerBio for use in cataract surgery. A Phase I clinical study in cataract patients and multiple preclinical rabbit studies showed a favorable safety profile, with no treatment-emergent adverse events related to the study drug, no serious adverse events, and no safety issues linked to the drug delivery platform.
In the human study, reported adverse events were in line with expectations for cataract surgery and consistent with patients’ prior eye conditions, while the investigational product and intraocular lens remained properly positioned in all treated eyes. Preclinical studies similarly showed good local tolerability and no tissue abnormalities compared with control. These findings support continued development and IND-enabling work in the United States for OcuRing™-K’s intraocular system, which is designed for targeted, sustained release of NSAIDs, corticosteroids, or other ophthalmic drugs from a single intraoperative application.
PainReform Ltd. reports updated financial information related to its acquisition of LayerBio Inc. The company is acquiring 7,331,378 shares of LayerBio preferred stock, which at closing will represent 51% of LayerBio’s fully diluted share capital under a Preferred Stock Purchase Agreement dated July 8, 2025.
This filing provides three key exhibits: unaudited pro forma condensed combined financial information for PainReform as if the LayerBio acquisition had occurred on January 1, 2024 and on June 30, 2025, audited financial statements of LayerBio for the years ended December 31, 2024 and 2023, and unaudited condensed financial statements of LayerBio for the six months ended June 30, 2025. PainReform notes that the pro forma figures are illustrative only and do not necessarily represent past or future results.
PainReform Ltd. reported that it has scheduled its Annual General Meeting of Shareholders for December 30, 2025, at 3:00 p.m. Israel time. The meeting will take place at the offices of the company’s legal counsel, Amit, Pollak, Matalon & Co., in Tel Aviv, Israel. To support the meeting, PainReform is providing a Notice and Proxy Statement and a Proxy Card for holders of ordinary shares so shareholders can review the agenda and vote their shares in advance or by proxy.
PainReform Ltd. (PRFX) furnished a Form 6-K noting it issued a press release on November 12, 2025 titled “PainReform’s DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis.” The release is attached as Exhibit 99.1 and incorporated by reference. The filing provides the exhibit index and signature by Ehud Geller, Executive Chairman and Interim Chief Executive Officer.
PainReform Ltd. (PRFX) filed a Form 6-K noting it issued a press release on November 5, 2025 titled “PainReform’s DeepSolar, Developing ‘DeepSolar Predict’ within the NVIDIA Connect Program, Featured in The Market Link’s ‘Watchlist Interview’ and Announces Progress Toward Pilot Projects.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The report is signed by Ehud Geller, Executive Chairman of the Board and Interim Chief Executive Officer.
PainReform Ltd. filed a Form 6-K reporting that on October 1, 2025 it issued a press release announcing its financial results for the six months ended June 30, 2025 and furnished unaudited condensed financial statements and an operating and financial review for that period.
The filing also discloses a board change: Professor Eli Hazum resigned effective September 30, 2025 for personal reasons, expressly not due to any disagreement with management, and Asaf Shavit was appointed to the Board effective immediately; Mr. Shavit is a Certified Public Accountant with 35+ years of audit, tax and financial advisory experience.
PainReform Ltd., an Israel-based company, submitted a Form 6-K as a foreign private issuer. The report notes that on August 19, 2025, the company issued a press release titled “PainReform/DeepSolar Accepted into NVIDIA Connect Program.” The press release is furnished as Exhibit 99.1.
The filing is informational, formally placing this collaboration-related announcement into the company’s official U.S. disclosure record. No financial figures, deal terms, or operational metrics are included in this excerpt.
PainReform Ltd. completed a strategic investment in LayerBio to enter the global cataract surgery market, described in the filing as a $9 billion opportunity, via a non-opiate, non-steroidal postoperative NSAID drug delivery system. The report attaches the press release as Exhibit 99.1 and states the first paragraph of that release is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements.
The filing is a disclosure of the investment and the attached press release; it does not provide financial terms, clinical data, or operational results within the text of the Form 6-K itself.